Ectopic expression of activation-induced cytidine deaminase caused by epigenetics modification

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 153-158

  Tatemichi, Masayuki ^a   Hata, Nakadate ^a   Toshio, Harumi ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Activation induced cytidine deaminase; Histone deacetylase inhibitor; Inducible nitricoxide synthase; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACTIVATION INDUCED CYTIDINE DEAMINASE; BUTYRIC ACID; CYTIDINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; S NITROSOGLUTATHIONE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ARTICLE; CANCER CELL; CELL STIMULATION; COPY NUMBER VARIATION; DEAMINATION; DNA METHYLATION; DNA MODIFICATION; DRUG EFFECT; EPIGENETICS; EXON; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYTIDINE DEAMINASE; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78650728657     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001055     Document Type: Article

References (23)

1. Muramatsu M., Kinoshita K., Fagarasan S., Yamada S., Shinkai Y., Honjo T.:Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553-563, 2000.
2. Muto T., Muramatsu M., Taniwaki M., Kinoshita K., Honjo T.: Isolation, tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene. Genomics 68: 85-88, 2000.
3. Komori J., Marusawa H., Machimoto T., et al.: Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 47: 888-896, 2008.
4. Endo Y., Marusawa H., Kinoshita K., et al.: Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 26: 5587-5595, 2007. (Pubitemid 47267836)
5. Matsumoto Y., Marusawa H., Kinoshita K., et al.: Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 13: 470-476, 2007.
6. Takai A., Toyoshima T., Uemura M., et al.: A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations. Oncogene 28: 469-478, 2009.
7. Forstermann U., Kleinert H.: Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch Pharmacol 352: 351-364, 1995.
8. Lala P.K., Chakraborty C.: Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2: 149-156, 2001.
9. Ogura T, DeGeorge G, Tatemichi M and Esumi H: Suppression of anti-microtubule agent-induced apoptosis by nitric oxide:possible mechanism of a new drug resistance. Jpn J Cancer Res 89: 199-205, 1998.
10. Fukunaga-Takenaka R, Fukunaga K, Tatemichi M and Ohshima H: Nitric oxide prevents UV-induced phosphorylation of the p53 tumor-suppressor protein at serine 46: a possible role in inhibition of apoptosis. Biochem Biophys Res Commun 308: 966-974, 2003.
11. Chin K., Kurashima Y., Ogura T., Tajiri H., Yoshida S., Esumi H.: Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene 15: 437-442, 1997.
12. Ishii Y., Ogura T., Tatemichi M., Fujisawa H., Otsuka F., Esumi H.: Induction of matrix metalloproteinase gene transcription by nitric oxide and mechanisms of MMP-1 gene induction in human melanoma cell lines. Int J Cancer 103: 161-168, 2003.
13. Tatemichi M., Tazawa H., Masuda M., et al.: Suppression of thymic lymphomas and increased non-thymic lymphomagenesis in Trp53-deficient mice lacking inducible nitric oxide synthase gene. Int J Cancer 111: 819-828, 2004.
14. Tatemichi M., Ogura T., Esumi H.: Impact of inducible nitric oxide synthase gene on tumor progression. Eur J Cancer Prev 18: 1-8, 2009.
15. Wink D.A., Kapspzak K.S., Maragos C.M. et al.: DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 254: 1001-1003, 1991.
16. Ushijima T., Okochi-Takada E.: Aberrant methylations in cancer cells: where do they come from? Cancer Sci 96: 206-211, 2005.
17. Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis 31: 27-36, 2010.
18. Ohshima H, Tatemichi M and Sawa T: Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 417: 3-11, 2003.
19. Tatemichi M, Hata H, Tazawa H and Nakadate T: Lipopolysaccharide induces aberrant hypermethylation of Hic-1 in mouse embryonic fibroblasts lacking p53 gene. Anticancer Res 28: 2101-2108, 2008.
20. Chan GC, Fish JE, Mawji IA, Leung DD, Rachlis AC and Marsden PA: Epigenetic basis for the transcriptional hyporesponsiveness of the human inducible nitric oxide synthase gene in vascular endothelial cells. J Immunol 175: 3846-3861, 2005.
21. Chiba T and Marusawa H: A novel mechanism for inflammationassociated carcinogenesis; an important role of activationinduced cytidine deaminase (AID) in mutation induction. J Mol Med 87: 1023-1027, 2009.
22. Ambs S, Ogunfusika MO, Merriam WG, Bennett WP, Billiar TR and Harris CC: Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci USA 95: 8823-8828, 1998.
23. Hashimoto K, Oreffo, Gibson, et al: DNA demethylation at specific CpG in the IL1B promoter in response to inflammatory cytokines in human articular chonrocytes. Arthritis Rheum 60: 3303-3313, 2009.